Characteristics of Glucocorticoid Resistance in Ankylosing Spondylitis

Abstract

Despite the fact that significant progress has been made in the treatment of ankylosing spondylitis, and basic drugs (methotrexate, sulfosalazine, etc.) are widely used, as well as various genetically engineered drugs that make it possible to achieve remission of the disease, glucocorticoid hormones continue to be one of the means of treating the disease, because they allow to achieve a sufficiently rapid decrease in the activity of the disease, as well as in the presence of systemic manifestations. Their use allows to reduce inflammatory activity, to stop the symptoms of inflammation and thereby to ease the condition of patients. The authors have established a different degree of sensitivity to various glucocorticoids, which must be taken into account during treatment.